|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 43, 1939-1949, November 2002
Copyright © 2002 by Lipid Research, Inc.



















* Centre for Molecular Medicine and Therapeutics, Childrens' and Women's Hospital, University of British Columbia, 980 West 28th Avenue, Vancouver, British Columbia, Canada
Xenon Genetics, Inc., Vancouver, British Columbia, Canada
Pfizer Global Research, Ann Arbor, MI
** Graduate School of Medicine, Osaka University, Osaka, Japan

Cardiovascular Genetics Laboratory, University Health Centre, Montreal, Quebec, Canada

Academic Medical Centre, Amsterdam, The Netherlands
1 To whom correspondence should be addressed. e-mail: mrh{at}cmmt.ubc.ca
Mutations in ABCA1 uniformly decrease plasma HDL-cholesterol (HDL-C) and reduce cholesterol efflux, yet different mutations in ABCA1 result in different phenotypic effects in heterozygotes. For example, truncation mutations result in significantly lower HDL-C and apoliprotein A-I (apoA-I) levels in heterozygotes compared with nontruncation mutations, suggesting that truncation mutations may negatively affect the wild-type allele. To specifically test this hypothesis, we examined ABCA1 protein expression in response to 9-cis-retinoic acid (9-cis-RA) and 22-R-hydroxycholesterol (22-R-OH-Chol) in a collection of human fibroblasts representing eight different mutations and observed that truncation mutations blunted the response to oxysterol stimulation and dominantly suppressed induction of the remaining full-length allele to 510% of wild-type levels. mRNA levels between truncation and nontruncation mutations were comparable, suggesting that ABCA1 expression was suppressed at the protein level. Dominant negative activity of truncated ABCA1 was recapitulated in an in vitro model using transfected Cos-7 cells. Our results suggest that the severe reduction of HDL-C in patients with truncation mutations may be at least partly explained by dominant negative suppression of expression and activity of the remaining full-length ABCA1 allele.
These data suggest that ABCA1 requires a physical association with itself or other molecules for normal function and has important pharmacogenetic implications for individuals with truncation mutations.
Abbreviations: apoA-I, apolipoprotein A-I; apoA-II, apolipoprotein A-II; BMI, body mass index; 9-cis-RA, 9-cis-retinoic acid; FCS, fetal calf serum; FHA, hypoalphalipoproteinemia; GAPDH, glyceraldehyde phosphate dehydrogenase; 22-R-OH-Chol, 22-R-hydroxycholesterol; TD, Tangier Disease
Supplementary key words high density lipoprotein cholesterol cholesterol efflux pharmacogenomics
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. L. E. MacDonald, R. R. Singaraja, N. Bissada, P. Ruddle, R. Watts, J. M. Karasinska, W. T. Gibson, C. Fievet, J. E. Vance, B. Staels, et al. Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice J. Lipid Res., January 1, 2008; 49(1): 217 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. H. Tansley, B. L. Burgess, M. T. Bryan, Y. Su, V. Hirsch-Reinshagen, J. Pearce, J. Y. Chan, A. Wilkinson, J. Evans, K. E. Naus, et al. The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of {beta}-amyloid precursor protein J. Lipid Res., May 1, 2007; 48(5): 1022 - 1034. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Singaraja, H. Visscher, E. R. James, A. Chroni, J. M. Coutinho, L. R. Brunham, M. H. Kang, V. I. Zannis, G. Chimini, and M. R. Hayden Specific Mutations in ABCA1 Have Discrete Effects on ABCA1 Function and Lipid Phenotypes Both In Vivo and In Vitro Circ. Res., August 18, 2006; 99(4): 389 - 397. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Hirsch-Reinshagen, S. Zhou, B. L. Burgess, L. Bernier, S. A. McIsaac, J. Y. Chan, G. H. Tansley, J. S. Cohn, M. R. Hayden, and C. L. Wellington Deficiency of ABCA1 Impairs Apolipoprotein E Metabolism in Brain J. Biol. Chem., September 24, 2004; 279(39): 41197 - 41207. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Selva, V. Hirsch-Reinshagen, B. Burgess, S. Zhou, J. Chan, S. McIsaac, M. R. Hayden, G. L. Hammond, A. W. Vogl, and C. L. Wellington The ATP-binding cassette transporter 1 mediates lipid efflux from Sertoli cells and influences male fertility J. Lipid Res., June 1, 2004; 45(6): 1040 - 1050. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Krimbou, M. Denis, B. Haidar, M. Carrier, M. Marcil, and J. Genest Jr. Molecular interactions between apoE and ABCA1: impact on apoE lipidation J. Lipid Res., May 1, 2004; 45(5): 839 - 848. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Wellington, L. R. Brunham, S. Zhou, R. R. Singaraja, H. Visscher, A. Gelfer, C. Ross, E. James, G. Liu, M. T. Huber, et al. Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1 J. Lipid Res., August 1, 2003; 44(8): 1470 - 1480. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Singaraja, L. R. Brunham, H. Visscher, J. J.P. Kastelein, and M. R. Hayden Efflux and Atherosclerosis: The Clinical and Biochemical Impact of Variations in the ABCA1 Gene Arterioscler. Thromb. Vasc. Biol., August 1, 2003; 23(8): 1322 - 1332. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. K. Hovingh, M. J. A. van Wijland, A. Brownlie, R. J. Bisoendial, M. R. Hayden, J. J. P. Kastelein, and A. K. Groen The role of the ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemia J. Lipid Res., June 1, 2003; 44(6): 1251 - 1255. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |